°øÁö»çÇ×

HOME > ÇÐȸ¼Ò°³   >   °øÁö»çÇ×

¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú ¿¬¼ö°­Á °³ÃÖ ¾È³»
ÀÛ¼ºÀÚ
°ü¸®ÀÚ
÷ºÎÆÄÀÏ
ÀÛ¼ºÀÏ
2009-03-04
Á¶È¸
6078


2009³â ¼­¿ï´ëÇб³º´¿ø Ç÷¾×Á¾¾ç³»°ú ¿¬¼ö°­Á¸¦ ¾Æ·¡¿Í °°ÀÌ °³ÃÖÇÏ¿À´Ï ȸ¿ø ¿©·¯ºÐÀÇ ¸¹Àº °ü½É°ú Âü¿©¸¦ ºÎŹµå¸³´Ï´Ù.

ÀÏÁ¤ ¹× ±âŸ ÀÚ¼¼ÇÑ ³»¿ëÀº ÷ºÎÆÄÀÏÀ» Âü°íÇϽñ⠹ٶø´Ï´Ù.

- ¾Æ·¡ -

ÀϽà : 2009³â 4¿ù 10ÀÏ(±Ý) 13:00~18:55

Àå¼Ò : ¼­¿ï´ëÇб³º´¿ø ÀÓ»óÀÇÇבּ¸¼Ò ´ë°­´ç

ÆòÁ¡ : ´ëÇÑÀÇ»çÇùȸ 4Á¡, Ç÷¾×Á¾¾çºÐ°úÀü¹®ÀÇ 4Á¡

»çÀüµî·Ï ¸¶°¨: 2009³â 3¿ù 31ÀÏ(È­)

¹®ÀÇó : TEL : 02-2072-2199, E-mail : snuhmo@hanmail.net

ÀÏÁ¤Ç¥

1 ºÎ ÁÂÀå: ±èº´±¹ (¼­¿ïÀÇ´ë)

13:00-13:20 The role of allogeneic HSCT in acute lymphoblastic leukemia ÁÖ¿µµ· (ÀÎÁ¦ÀÇ´ë)
13:20-13:40 Use of allogeneic HSCT in acute myelogenous leukemia ±èÀÎÈ£ (¼­¿ïÀÇ´ë)
13:40-14:00 Updates of graft-versus-host disease ¹Ú¼±¾ç (¼­¿ïÀÇ´ë)
14:00-14:20 Discussion


2 ºÎ ÁÂÀå: ¹Ú¼±¾ç (¼­¿ïÀÇ´ë)


14:20-14:50 Imatinib resistance and choosing the 2nd line TKI in CML Arinobu Tojo (The Institute of Medical Science, The University of Tokyo)
14:50-15:10 Biology and treatment of primary myelofibrosis ¹æ¼ö¹Ì (¼­¿ïÀÇ´ë)
15:10-15:30 Epigenetic therapy in myelodysplastic syndrome ÀÌÁ¦È¯ (¿ï»êÀÇ´ë)

15:30-15:50 Discussion

15:50-16:10 ÈÞ½Ä


3 ºÎ ÁÂÀå: ÀÌÁ¾¿í (°¡Å縯ÀÇ´ë)


16:10-16:30 Aplastic anemia: Pathogenesis and treatment ÀÌÁ¾¿í (°¡Å縯ÀÇ´ë)
16:30-16:50 Anticoagulation therapy for venous thromboembolism ¿Àµµ¿¬ (Æ÷õÁß¹®ÀÇ´ë)
16:50-17:10 Novel treatments for chronic immune thrombocytopenic purpura ¹ÚÀº°æ (Áß¾ÓÀÇ´ë)

17:10-17:30 Discussion


4 ºÎ ÁÂÀå: ¼­Ã¶¿ø (¿ï»êÀÇ´ë)


17:30-17:50 Recent updates of multiple myeloma À±¼º¼ö (¼­¿ïÀÇ´ë)
17:50-18:10 Monoclonal antibody therapies for B-cell lymphomas À̽ÂÅ (¿¬¼¼ÀÇ´ë)
18:10-18:30 Prognosis and therapy of PTCL ±è¼®Áø (¼º±Õ°üÀÇ´ë)

18:30-18:50 Discussion

18:50-18:55 Closing remark ±èº´±¹ (¼­¿ïÀÇ´ë)